<DOC>
	<DOCNO>NCT02833753</DOCNO>
	<brief_summary>This Phase I dose escalation study determine much chemotherapy safely administer abdomen experience few possible side effect .</brief_summary>
	<brief_title>Trial Intraperitoneal ( IP ) Oxaliplatin Combination With Intravenous FOLFIRI</brief_title>
	<detailed_description>There two common combination chemotherapy drug use treat cancer colon , rectum , appendix spread abdomen . One use 5-fluorouracil ( also call 5-FU ) , leucovorin oxaliplatin , call FOLFOX . The uses 5-FU , leucovorin , irinotecan , call FOLFIRI . The Food Drug Administration ( FDA ) approve combination treatment colon rectal cancer . Each give vein . FOLFOX FOLFIRI work well tumor grow abdominal cavity . The investigator try determine give chemotherapy call oxaliplatin directly abdominal cavity great effect cancer . The FDA approve oxaliplatin give people vein treat advanced colorectal cancer . Giving oxaliplatin directly abdomen study experimental approve FDA . This study give standard chemotherapy FOLFIRI vein oxaliplatin directly abdomen . This first time intraperitoneal oxaliplatin give combination FOLFIRI .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>The patient must 18 year age old capable providing inform consent indicate awareness investigational nature trial , keep institutional policy Patients must willing return followup The patient must consent participate trial must sign approve informed consent form conform institutional policy The patient must histopathologically cytologically confirm colon , rectal appendiceal adenocarcinoma synchronous metachronous peritoneal dissemination disease . ( Stage IV peritoneal base disease ) The patient must active measurable disease either abdominal computerized axial tomography ( CT ) / Magnetic resonance imaging ( MRI ) laparoscopy . At time enrollment , patient must : ( within 14 day enrollment ) Absolute neutrophil count ( ANC ) &gt; 1200/mm3 platelet count &gt; 140,000/mm3 An international normalized ratio ( INR ) ≤ 1.5 ( patient therapeutically anticoagulated nonrelated medical condition atrial fibrillation whose anti thrombotic treatment withheld operation eligible ) Adequate hepatic function must meet evidenced total serum bilirubin ≤ 1.5 mg/dl ( patient total bilirubin &gt; 1.5 mg/dL eligible Gilbert 's syndrome ) ; alkaline phosphatase &lt; 2.5 time upper limit normal ; , aspartate aminotransferase ( AST ) less 1.5 time upper limit normal [ alkaline phosphatase AST exceed upper limit normal ] Serum renal functional parameter , blood urea nitrogen ( BUN ) creatinine within normal limit ( estimate glomerular filtration rate ( eGFR ) &gt; 50 ) Prior enrollment patient must complete history physical examination , electrocardiogram , within three month enrollment Satisfactory cardiopulmonary function ( determined Physician ) Patients receive prior systemic chemotherapy , radiation surgery Patients must able undergo placement intraperitoneal ( IP ) catheter PortA Cath , already present Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less Women reproductive age men sexually active must willing practice effective contraception Patients allow secondary malignancy long require active concomitant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>